1 month Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of “Moderate Buy” from BrokeragesMarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock wit…
X